Peregrine is semi pleased to announce Bavituximab performed potentially well in the SUNRISE PIII trial. Both efficacy and safety were within expected ranges. Full data from the trial may, may not, possibly could be, but most likely will never be presented at a future scientific conference. For more information on Bavituximab, please send a text message to PPHM IR at 555-GET-POOR.
Something always goes wrong with Peregrine trials. Outlier results from outside the US, unusually good SOC arm results, better results from lower dosage, differences in opinion of results from independent review, and of course botching the whole damn P2 trial.
What will they come up with next?
Market Data 
Markets 
AI
